| Insideraktier | 5.551 shares |
| Total Insiders | 25 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
BlackRock Health Sciences Trust insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Christopher Accettella - | 821 | 821 | |
| Janey Ahn | 0 | ||
| Richard Cavanagh | 1.691 | ||
| Michael J Castellano Director - [D] | 400 | 400 | |
| Robert Crothers | 0 | ||
| Jonathan Diorio | 0 | ||
| Cynthia Egan Director - [D] | 3.737 | 3.737 | |
| Frank Fabozzi | 142 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Kathleen F Feldstein | 484 | ||
| James T Flynn | 882 | ||
| Robert W Fairbairn | 0 | ||
| Henry Gabbay Director - [D] | 0 | 0 | |
| Robert Glenn Hubbard | 2.941 | ||
| Jerrold B Harris | 2.373 | ||
| W Carl Kester | 1.343 | ||
| Jeffrey Gene Lee - | 0 | 0 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Xiang Liu - | 0 | 0 | |
| Lynch Catherine A. | 474 | ||
| Kyle McClements - | 593 | 593 | |
| Barbara Novick | 0 | ||
| Charles Park | 0 | ||
| John F Powers | 0 | ||
| Karen P Robards | 619 | ||
| Trent Walker | 0 | ||
| H Erin Xie - | 0 | 0 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BME / BlackRock Health Sciences Trust. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BME / BlackRock Health Sciences Trust. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-09 | GABBAY HENRY | 650 | 42,1916 | 650 | 42,1916 | 27.425 | 293 | 36.5692 | -3.654 | -13,32 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-04 | 2025-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 40,9200 | -13.471 | -551 | 0 | ||||
| 2025-02-04 | 2025-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 13.471 | 13.471 | ||||||
| 2025-02-04 | 2025-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 40,9200 | -281 | -11 | 0 | ||||
| 2025-02-04 | 2025-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 281 | 281 | ||||||
| 2025-02-04 | 2025-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 40,9200 | -202 | -8 | 821 | ||||
| 2025-02-04 | 2025-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 202 | 1.023 | ||||||
| 2025-02-04 | 2025-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 40,9200 | -641 | -26 | 593 | ||||
| 2025-02-04 | 2025-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 641 | 1.234 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 41,4800 | -626 | -26 | 2.736 | ||||
| 2024-02-02 | 2024-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 626 | 3.361 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 41,4800 | -14.947 | -620 | 0 | ||||
| 2024-02-02 | 2024-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 14.947 | 14.947 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 41,4800 | -203 | -8 | 770 | ||||
| 2024-02-02 | 2024-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 203 | 972 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 41,4800 | -189 | -8 | 0 | ||||
| 2024-02-02 | 2024-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 189 | 189 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 43,5600 | -96 | -4 | 0 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Liu Xiang | BME | Common Stock | D | 96 | 96 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 43,5600 | -616 | -27 | 522 | ||||
| 2023-02-02 | 2023-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 616 | 1.138 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 43,5600 | -13.967 | -608 | 0 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 13.967 | 13.967 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 43,5600 | -206 | -9 | 722 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 206 | 928 | ||||||
| 2023-02-02 | 2023-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 43,5600 | -205 | -9 | 0 | ||||
| 2023-02-02 | 2023-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 205 | 205 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | -287 | 0 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | -144 | 144 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | -201 | 401 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 45,1000 | 707 | 32 | 707 | ||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 45,1000 | -632 | -29 | 494 | ||||
| 2022-02-03 | 2022-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 632 | 1.126 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | -78 | 0 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | -64 | 64 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | -61 | 123 | ||||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 45,1000 | 208 | 9 | 208 | ||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 45,1000 | -203 | -9 | 684 | ||||
| 2022-02-03 | 2022-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 203 | 887 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Phantom Shares | D | -71 | 143 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Phantom Shares | D | 45,1000 | 364 | 16 | 364 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 45,1000 | -71 | -3 | 0 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Lee Jeffrey Gene | BME | Common Stock | D | 71 | 71 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -7.518 | 0 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -3.739 | 3.739 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -4.359 | 8.719 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 45,1000 | 15.174 | 684 | 15.174 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 45,1000 | -15.617 | -704 | 0 | ||||
| 2022-02-02 | 2022-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 15.617 | 15.617 | ||||||
| 2022-02-02 | 2022-01-31 | 4 | Liu Xiang | BME | Phantom Shares | D | 45,1000 | 272 | 12 | 272 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | -93 | 0 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | -74 | 74 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | -60 | 121 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Phantom Shares | D | 47,8800 | 175 | 8 | 175 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Common Stock | D | 47,8800 | -228 | -11 | 649 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Accettella Christopher | BME | Common Stock | D | 228 | 877 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | -366 | 0 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | -273 | 273 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | -137 | 274 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Phantom Shares | D | 47,8800 | 572 | 27 | 572 | ||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Common Stock | D | 47,8800 | -776 | -37 | 469 | ||||
| 2021-02-02 | 2021-01-29 | 4 | McClements Kyle | BME | Common Stock | D | 776 | 1.245 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Lee Jeffrey Gene | BME | Phantom Shares | D | 47,8800 | 204 | 10 | 204 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | -3.172 | 0 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | -7.143 | 7.143 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | -3.553 | 7.105 | ||||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Phantom Shares | D | 47,8800 | 12.425 | 595 | 12.425 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Common Stock | D | 47,8800 | -13.867 | -664 | 0 | ||||
| 2021-02-02 | 2021-01-29 | 4 | Xie H Erin | BME | Common Stock | D | 13.867 | 13.867 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | -346 | 346 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | -258 | 516 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 41,1200 | 393 | 16 | 393 | ||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 41,1200 | -604 | -25 | 443 | ||||
| 2020-02-04 | 2020-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 604 | 1.047 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -1.641 | 0 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -2.998 | 2.998 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -6.752 | 13.503 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 41,1200 | 10.178 | 419 | 10.178 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 41,1200 | -11.391 | -468 | 0 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 11.391 | 11.391 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | -88 | 88 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | -70 | 140 | ||||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 41,1200 | 173 | 7 | 173 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 41,1200 | -158 | -7 | 610 | ||||
| 2020-02-04 | 2020-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 158 | 769 | ||||||
| 2019-07-02 | 2019-06-28 | 4 | Egan Cynthia | BME | Common Stock | D | 38,9200 | 3.737 | 145 | 3.737 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -1.544 | 1.544 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -2.820 | 5.640 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 39,6700 | 19.052 | 756 | 19.052 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 39,6700 | -4.364 | -173 | 0 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 4.364 | 4.364 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | -325 | 651 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 39,6700 | 728 | 29 | 728 | ||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 39,6700 | -325 | -13 | 417 | ||||
| 2019-02-04 | 2019-01-31 | 4 | McClements Kyle | BME | Common Stock | D | 325 | 742 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | -83 | 166 | ||||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 39,6700 | 198 | 8 | 198 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 39,6700 | -83 | -3 | 577 | ||||
| 2019-02-04 | 2019-01-31 | 4 | Accettella Christopher | BME | Common Stock | D | 83 | 660 | ||||||
| 2018-10-17 | 2018-10-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 41,2500 | 32 | 1 | 1.343 | ||||
| 2018-10-17 | 2018-10-15 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 41,2500 | 50 | 2 | 474 | ||||
| 2018-10-17 | 2018-10-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 41,2500 | 17 | 1 | 619 | ||||
| 2018-10-17 | 2018-10-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 41,2500 | 75 | 3 | 1.783 | ||||
| 2018-10-17 | 2018-10-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 41,2500 | 109 | 5 | 1.691 | ||||
| 2018-10-17 | 2018-10-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 41,2500 | 125 | 5 | 2.941 | ||||
| 2018-07-17 | 2018-07-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 41,1700 | 126 | 5 | 2.773 | ||||
| 2018-07-17 | 2018-07-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 41,1700 | 32 | 1 | 1.291 | ||||
| 2018-07-17 | 2018-07-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 41,1700 | 50 | 2 | 418 | ||||
| 2018-07-17 | 2018-07-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 41,1700 | 17 | 1 | 593 | ||||
| 2018-07-17 | 2018-07-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 41,1700 | 75 | 3 | 1.682 | ||||
| 2018-07-17 | 2018-07-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 41,1700 | 109 | 5 | 1.557 | ||||
| 2018-04-17 | 2018-04-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 34,5200 | 59 | 2 | 362 | ||||
| 2018-04-17 | 2018-04-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 34,5200 | 20 | 1 | 567 | ||||
| 2018-04-17 | 2018-04-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 34,5200 | 89 | 3 | 1.581 | ||||
| 2018-04-17 | 2018-04-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 34,5200 | 130 | 5 | 1.424 | ||||
| 2018-04-17 | 2018-04-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 34,5200 | 150 | 5 | 2.604 | ||||
| 2018-04-17 | 2018-04-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 34,5200 | 38 | 1 | 1.238 | ||||
| 2018-02-02 | 2018-01-31 | 4 | McClements Kyle | BME | Phantom Shares | D | 36,2100 | 916 | 33 | 916 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Accettella Christopher | BME | Phantom Shares | D | 36,2100 | 234 | 8 | 234 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | -1.450 | 2.899 | ||||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 36,2100 | 7.946 | 288 | 7.946 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 36,2100 | -1.450 | -52 | 0 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Xie H Erin | BME | Common Stock | D | 1.450 | 1.450 | ||||||
| 2018-01-17 | 2018-01-12 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 36,5900 | 56 | 2 | 298 | ||||
| 2018-01-17 | 2018-01-12 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,5900 | 19 | 1 | 538 | ||||
| 2018-01-17 | 2018-01-12 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,5900 | 84 | 3 | 1.467 | ||||
| 2018-01-17 | 2018-01-12 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,5900 | 123 | 5 | 1.272 | ||||
| 2018-01-17 | 2018-01-12 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,5900 | 141 | 5 | 2.413 | ||||
| 2018-01-17 | 2018-01-12 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,5900 | 36 | 1 | 1.179 | ||||
| 2017-10-17 | 2017-10-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,7000 | 93 | 3 | 1.130 | ||||
| 2017-10-17 | 2017-10-13 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,7000 | 152 | 6 | 2.373 | ||||
| 2017-10-17 | 2017-10-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,7000 | 141 | 5 | 2.234 | ||||
| 2017-10-17 | 2017-10-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,7000 | 36 | 1 | 1.124 | ||||
| 2017-10-17 | 2017-10-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 36,7000 | 56 | 2 | 238 | ||||
| 2017-10-17 | 2017-10-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,7000 | 37 | 1 | 510 | ||||
| 2017-10-17 | 2017-10-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,7000 | 84 | 3 | 1.360 | ||||
| 2017-07-18 | 2017-07-14 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 37,1900 | 55 | 2 | 179 | ||||
| 2017-07-18 | 2017-07-14 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 37,1900 | 37 | 1 | 465 | ||||
| 2017-07-18 | 2017-07-14 | 4 | KESTER W CARL | BME | Performance Rights | D | 37,1900 | 36 | 1 | 1.070 | ||||
| 2017-07-18 | 2017-07-14 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 37,1900 | 139 | 5 | 2.058 | ||||
| 2017-07-18 | 2017-07-14 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 37,1900 | 92 | 3 | 1.019 | ||||
| 2017-07-18 | 2017-07-14 | 4 | Harris Jerrold B | BME | Performance Rights | D | 37,1900 | 150 | 6 | 2.184 | ||||
| 2017-07-18 | 2017-07-14 | 4 | Castellano Michael J | BME | Performance Rights | D | 37,1900 | 83 | 3 | 1.255 | ||||
| 2017-04-17 | 2017-04-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 34,2100 | 40 | 1 | 421 | ||||
| 2017-04-17 | 2017-04-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 34,2100 | 39 | 1 | 1.016 | ||||
| 2017-04-17 | 2017-04-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 34,2100 | 151 | 5 | 1.886 | ||||
| 2017-04-17 | 2017-04-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 34,2100 | 60 | 2 | 122 | ||||
| 2017-04-17 | 2017-04-13 | 4 | Harris Jerrold B | BME | Performance Rights | D | 34,2100 | 163 | 6 | 1.999 | ||||
| 2017-04-17 | 2017-04-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 34,2100 | 100 | 3 | 912 | ||||
| 2017-04-17 | 2017-04-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 34,2100 | 90 | 3 | 1.152 | ||||
| 2017-03-27 | 2017-01-31 | 4 | Xie H Erin | BME | Phantom Shares | D | 33,1200 | 4.062 | 135 | 4.062 | ||||
| 2017-01-18 | 2017-01-13 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 33,6500 | 101 | 3 | 798 | ||||
| 2017-01-18 | 2017-01-13 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 33,6500 | 153 | 5 | 1.705 | ||||
| 2017-01-18 | 2017-01-13 | 4 | KESTER W CARL | BME | Performance Rights | D | 33,6500 | 39 | 1 | 961 | ||||
| 2017-01-18 | 2017-01-13 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 33,6500 | 41 | 1 | 374 | ||||
| 2017-01-18 | 2017-01-13 | 4 | Castellano Michael J | BME | Performance Rights | D | 33,6500 | 91 | 3 | 1.044 | ||||
| 2017-01-18 | 2017-01-13 | 4 | Harris Jerrold B | BME | Performance Rights | D | 33,6500 | 166 | 6 | 1.804 | ||||
| 2017-01-18 | 2017-01-13 | 4 | Lynch Catherine A. | BME | Performance Rights | D | 33,6500 | 61 | 2 | 61 | ||||
| 2016-10-18 | 2016-10-14 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 33,4300 | 41 | 1 | 672 | ||||
| 2016-10-18 | 2016-10-14 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 33,4300 | 154 | 5 | 1.495 | ||||
| 2016-10-18 | 2016-10-14 | 4 | KESTER W CARL | BME | Performance Rights | D | 33,4300 | 91 | 3 | 888 | ||||
| 2016-10-18 | 2016-10-14 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 33,4300 | 20 | 1 | 321 | ||||
| 2016-10-18 | 2016-10-14 | 4 | Castellano Michael J | BME | Performance Rights | D | 33,4300 | 92 | 3 | 918 | ||||
| 2016-10-18 | 2016-10-14 | 4 | Harris Jerrold B | BME | Performance Rights | D | 33,4300 | 167 | 6 | 1.579 | ||||
| 2016-07-19 | 2016-07-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 35,4800 | 19 | 1 | 296 | ||||
| 2016-07-19 | 2016-07-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 35,4800 | 145 | 5 | 1.319 | ||||
| 2016-07-19 | 2016-07-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 35,4800 | 37 | 1 | 620 | ||||
| 2016-07-19 | 2016-07-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 35,4800 | 85 | 3 | 784 | ||||
| 2016-07-19 | 2016-07-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 35,4800 | 86 | 3 | 812 | ||||
| 2016-07-19 | 2016-07-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 35,4800 | 157 | 6 | 1.389 | ||||
| 2016-04-19 | 2016-04-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,7600 | 37 | 1 | 574 | ||||
| 2016-04-19 | 2016-04-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,7600 | 19 | 1 | 272 | ||||
| 2016-04-19 | 2016-04-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,7600 | 140 | 5 | 1.154 | ||||
| 2016-04-19 | 2016-04-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,7600 | 83 | 3 | 687 | ||||
| 2016-04-19 | 2016-04-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,7600 | 83 | 3 | 714 | ||||
| 2016-04-19 | 2016-04-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,7600 | 151 | 6 | 1.212 | ||||
| 2016-01-20 | 2016-01-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 37,0400 | 83 | 3 | 620 | ||||
| 2016-01-20 | 2016-01-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 37,0400 | 150 | 6 | 1.043 | ||||
| 2016-01-20 | 2016-01-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 37,0400 | 41 | 2 | 527 | ||||
| 2016-01-20 | 2016-01-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 37,0400 | 139 | 5 | 997 | ||||
| 2016-01-20 | 2016-01-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 37,0400 | 82 | 3 | 594 | ||||
| 2016-01-20 | 2016-01-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 37,0400 | 20 | 1 | 249 | ||||
| 2015-10-19 | 2015-10-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 40,2500 | 138 | 6 | 879 | ||||
| 2015-10-19 | 2015-10-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 40,2500 | 128 | 5 | 846 | ||||
| 2015-10-19 | 2015-10-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 40,2500 | 76 | 3 | 529 | ||||
| 2015-10-19 | 2015-10-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 40,2500 | 72 | 3 | 484 | ||||
| 2015-10-19 | 2015-10-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 40,2500 | 127 | 5 | 882 | ||||
| 2015-10-19 | 2015-10-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 40,2500 | 66 | 3 | 505 | ||||
| 2015-10-19 | 2015-10-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 40,2500 | 34 | 1 | 226 | ||||
| 2015-10-19 | 2015-10-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 40,2500 | 14 | 1 | 142 | ||||
| 2015-10-19 | 2015-10-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 40,2500 | 72 | 3 | 479 | ||||
| 2015-07-16 | 2015-07-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 44,8800 | 61 | 3 | 447 | ||||
| 2015-07-16 | 2015-07-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 44,8800 | 99 | 4 | 732 | ||||
| 2015-07-16 | 2015-07-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 44,8800 | 96 | 4 | 708 | ||||
| 2015-07-16 | 2015-07-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 44,8800 | 11 | 0 | 126 | ||||
| 2015-07-16 | 2015-07-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 44,8800 | 55 | 2 | 402 | ||||
| 2015-07-16 | 2015-07-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 44,8800 | 55 | 2 | 407 | ||||
| 2015-07-16 | 2015-07-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 44,8800 | 101 | 5 | 745 | ||||
| 2015-07-16 | 2015-07-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 44,8800 | 59 | 3 | 434 | ||||
| 2015-07-16 | 2015-07-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 44,8800 | 26 | 1 | 190 | ||||
| 2015-04-17 | 2015-04-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 43,1400 | 11 | 0 | 114 | ||||
| 2015-04-17 | 2015-04-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 43,1400 | 105 | 5 | 637 | ||||
| 2015-04-17 | 2015-04-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 43,1400 | 27 | 1 | 162 | ||||
| 2015-04-17 | 2015-04-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 43,1400 | 57 | 2 | 348 | ||||
| 2015-04-17 | 2015-04-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 43,1400 | 100 | 4 | 606 | ||||
| 2015-04-17 | 2015-04-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 43,1400 | 57 | 2 | 344 | ||||
| 2015-04-17 | 2015-04-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 43,1400 | 61 | 3 | 371 | ||||
| 2015-04-17 | 2015-04-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 43,1400 | 63 | 3 | 382 | ||||
| 2015-04-17 | 2015-04-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 43,1400 | 103 | 4 | 625 | ||||
| 2015-01-20 | 2015-01-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 40,5000 | 106 | 4 | 501 | ||||
| 2015-01-20 | 2015-01-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 40,5000 | 110 | 4 | 516 | ||||
| 2015-01-20 | 2015-01-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 40,5000 | 67 | 3 | 315 | ||||
| 2015-01-20 | 2015-01-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 40,5000 | 61 | 2 | 287 | ||||
| 2015-01-20 | 2015-01-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 40,5000 | 112 | 5 | 526 | ||||
| 2015-01-20 | 2015-01-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 40,5000 | 65 | 3 | 306 | ||||
| 2015-01-20 | 2015-01-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 40,5000 | 29 | 1 | 134 | ||||
| 2015-01-20 | 2015-01-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 40,5000 | 12 | 0 | 102 | ||||
| 2015-01-20 | 2015-01-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 40,5000 | 60 | 2 | 284 | ||||
| 2014-12-11 | 2014-12-09 | 4 | GABBAY HENRY | BME | Common Stock | D | 42,1916 | -650 | -27 | 0 | ||||
| 2014-12-09 | 2014-12-05 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 42,9500 | 1 | 0 | 210 | ||||
| 2014-12-09 | 2014-12-05 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 42,9500 | 4 | 0 | 370 | ||||
| 2014-12-09 | 2014-12-05 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 42,9500 | 1 | 0 | 212 | ||||
| 2014-12-09 | 2014-12-05 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 42,9500 | 1 | 0 | 84 | ||||
| 2014-10-17 | 2014-10-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 36,0100 | 27 | 1 | 82 | ||||
| 2014-10-17 | 2014-10-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 36,0100 | 126 | 5 | 384 | ||||
| 2014-10-17 | 2014-10-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,0100 | 32 | 1 | 98 | ||||
| 2014-10-17 | 2014-10-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 36,0100 | 69 | 2 | 210 | ||||
| 2014-10-17 | 2014-10-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,0100 | 119 | 4 | 363 | ||||
| 2014-10-17 | 2014-10-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,0100 | 68 | 2 | 207 | ||||
| 2014-10-17 | 2014-10-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,0100 | 73 | 3 | 224 | ||||
| 2014-10-17 | 2014-10-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,0100 | 76 | 3 | 231 | ||||
| 2014-10-17 | 2014-10-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,0100 | 124 | 4 | 377 | ||||
| 2014-07-17 | 2014-07-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 36,4000 | 27 | 1 | 55 | ||||
| 2014-07-17 | 2014-07-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 36,4000 | 125 | 5 | 257 | ||||
| 2014-07-17 | 2014-07-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 36,4000 | 118 | 4 | 243 | ||||
| 2014-07-17 | 2014-07-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 36,4000 | 32 | 1 | 65 | ||||
| 2014-07-17 | 2014-07-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 36,4000 | 67 | 2 | 138 | ||||
| 2014-07-17 | 2014-07-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 36,4000 | 68 | 2 | 140 | ||||
| 2014-07-17 | 2014-07-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 36,4000 | 73 | 3 | 150 | ||||
| 2014-07-17 | 2014-07-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 36,4000 | 75 | 3 | 154 | ||||
| 2014-07-17 | 2014-07-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 36,4000 | 123 | 4 | 252 | ||||
| 2014-04-17 | 2014-04-15 | 4 | HUBBARD ROBERT GLENN | BME | Performance Rights | D | 34,9100 | 123 | 4 | 123 | ||||
| 2014-04-17 | 2014-04-15 | 4 | CAVANAGH RICHARD | BME | Performance Rights | D | 34,9100 | 70 | 2 | 70 | ||||
| 2014-04-17 | 2014-04-15 | 4 | KESTER W CARL | BME | Performance Rights | D | 34,9100 | 76 | 3 | 76 | ||||
| 2014-04-17 | 2014-04-15 | 4 | FLYNN JAMES T | BME | Performance Rights | D | 34,9100 | 130 | 5 | 130 | ||||
| 2014-04-17 | 2014-04-15 | 4 | FABOZZI FRANK | BME | Performance Rights | D | 34,9100 | 28 | 1 | 28 | ||||
| 2014-04-17 | 2014-04-15 | 4 | FELDSTEIN KATHLEEN F | BME | Performance Rights | D | 34,9100 | 71 | 2 | 71 | ||||
| 2014-04-17 | 2014-04-15 | 4 | ROBARDS KAREN P | BME | Performance Rights | D | 34,9100 | 33 | 1 | 33 | ||||
| 2014-04-17 | 2014-04-15 | 4 | Castellano Michael J | BME | Performance Rights | D | 34,9100 | 78 | 3 | 78 | ||||
| 2014-04-17 | 2014-04-15 | 4 | Harris Jerrold B | BME | Performance Rights | D | 34,9100 | 128 | 4 | 128 | ||||
| 2012-09-19 | 2012-09-19 | 4 | Castellano Michael J | BME | Common Stock | D | 27,7099 | 400 | 11 | 400 | ||||
| 2012-09-14 | 3 | Accettella Christopher | BME | Common Stock | D | 304 | ||||||||
| 2005-12-16 | 2005-12-06 | 4/A | McClements Kyle | BME | Common Stock | D | 25,3600 | 100 | 3 | 100 | ||||
| 2005-12-08 | 2005-12-06 | 4 | McClements Kyle | BME | Common Stock | D | 25,3600 | 100 | 3 | 100 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
